747 studies found for:    EGF
Show Display Options
Rank Status Study
1 Not yet recruiting Safety & Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild Type EGF-R NSCLC Patients
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Biological: EGF Vaccine
2 Recruiting A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies
Condition: NSCLC
Intervention: Drug: EGF816
3 Completed
Has Results
Effect of EGF With Silver Sulfadiazine Cream Compared With Silver Zinc Sulfadiazine Cream for Treatment of Burn Wound
Condition: Deep Partial Thickness Burn
Interventions: Drug: Epidermal growth factor with silver sulfadiazine cream;   Drug: Silver zinc sulfadiazine cream
4 Recruiting EGF Ointment for Erlotinib Skin Lesion
Conditions: Non-small Cell Lung Cancer;   Pancreatic Cancer
Intervention: Drug: Epidermal growth factor (EGF) ointment
5 Completed Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma
Conditions: Colorectal Cancer;   Carcinoma
Intervention: Drug: ABX-EGF
6 Completed
Has Results
ABX-EGF (Panitumumab) Monotherapy in Subjects With Metastatic Colorectal Cancer
Conditions: Colorectal Cancer;   Metastases
Intervention: Drug: ABX-EGF (panitumumab)
7 Completed Study About Preventive Treatment of Folliculitis Induced by Epidermal Growth Factor Receptor Inhibitors
Conditions: Metastatic Colorectal Cancer;   Non-Small-Cell Lung Carcinoma
Intervention: Drug: Diprosone
8 Terminated A Randomized Trial to Study the Safety and Efficacy of EGF Cancer Vaccination in Late-stage (IIIB/IV) Non-small Cell Lung Cancer Patients
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Biological: Therapeutic EGF Vaccine (Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine)
9 Completed Laryngeal and Esophageal EGF-r Expression in Patients With Reflux Laryngitis
Conditions: Gastroesophageal Reflux Disease (GERD);   Chronic Laryngitis
Interventions: Procedure: Biopsy of the retrocrycoid laryngeal mucosa;   Procedure: Biopsy of the distal esophageal mucosa
10 Unknown  A Physiological Study on Downregulation of EGF-receptors in the Skin by Topical Exposition With EGF
Condition: Plaque Psoriasis
Interventions: Drug: Human recombinant epidermal growth factor;   Other: Placebo cream
11 Completed ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Conditions: Non-small Cell Lung Cancer;   Neoplasm Metastasis;   Lung Cancer
Intervention: Drug: ABX-EGF
12 Completed Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal Cancer
Condition: Colorectal Cancer
Intervention: Drug: ABX-EGF
13 Completed Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer
Condition: Metastatic Colorectal Cancer
Intervention: Drug: ABX-EGF (panitumumab)
14 Completed ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body
Condition: Prostate Cancer
Intervention: Drug: ABX-EGF
15 Completed Salivary Epidermal Growth Factor (EGF) Concentration Before and After Treatment of Reflux Laryngitis
Conditions: Gastroesophageal Reflux Disease (GERD);   Chronic Laryngitis
Intervention: Drug: omeprazole
16 Completed
Has Results
Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer
Conditions: Colorectal Cancer;   Metastases
Interventions: Other: Best supportive care;   Drug: Panitumumab
17 Completed ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Conditions: Non-Small Cell Lung Cancer;   Neoplasm Metastasis;   Lung Cancer
Interventions: Drug: ABX-EGF;   Drug: paclitaxel;   Drug: carboplatin
18 Completed
Has Results
Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Drug: Irinotecan;   Biological: Panitumumab;   Drug: 5-Fluorouracil;   Drug: Leucovorin
19 Completed
Has Results
Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy
Conditions: Colorectal Cancer;   Metastatic Cancer
Intervention: Biological: Panitumumab
20 Active, not recruiting Observational Study to Characterize the Incidence of EGFR Mutation Positive and Advanced NSCLC Patients
Condition: Metastatic Non-Small-Cell Lung Cancer
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years